Myriad Genetics, Inc (MYGN) concluded trading on Thursday at a closing price of $14.50, with 2.68 million shares of worth about $38.92 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -37.74% during that period and on December 12, 2024 the price saw a loss of about -0.07%. Currently the company’s common shares owned by public are about 91.00M shares, out of which, 87.62M shares are available for trading.
Stock saw a price change of -11.37% in past 5 days and over the past one month there was a price change of -10.33%. Year-to-date (YTD), MYGN shares are showing a performance of -24.24% which decreased to -23.88% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $14.34 but also hit the highest price of $29.30 during that period. The average intraday trading volume for Myriad Genetics, Inc shares is 821.86K. The stock is currently trading -6.97% below its 20-day simple moving average (SMA20), while that difference is down -24.72% for SMA50 and it goes to -36.85% lower than SMA200.
Myriad Genetics, Inc (NASDAQ: MYGN) currently have 91.00M outstanding shares and institutions hold larger chunk of about 100.22% of that.
The stock has a current market capitalization of $1.32B and its 3Y-monthly beta is at 1.88. It has posted earnings per share of -$1.30 in the same period. It has Quick Ratio of 1.73 while making debt-to-equity ratio of 0.20. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MYGN, volatility over the week remained 8.16% while standing at 5.08% over the month.
Stock’s fiscal year EPS is expected to rise by 147.49% while it is estimated to increase by 28.42% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on December 10, 2024 offering a Neutral rating for the stock and assigned a target price of $18 to it. Coverage by Leerink Partners stated Myriad Genetics, Inc (MYGN) stock as a Market perform in their note to investors on December 09, 2024, suggesting a price target of $21 for the stock. On September 19, 2024, Morgan Stanley Initiated their recommendations, while on August 28, 2024, Wells Fargo Initiated their ratings for the stock with a price target of $35. Stock get a Sector outperform rating from Scotiabank on June 27, 2024.
